Drug and Lifestyle
What we do?
Our group recognise that in order to embed physical activity interventions within routine care pathways for diabetes management, we need to better understand how physical activity interacts with other prescribed therapies in the promotion of whole body health. We have an ongoing portfolio of research investigating whether exercise training can be combined with newer generations of glucose lowering therapies to provide synergistic benefits to health.
Members
Highlighted Research
Jobanputra R, Sargeant JA, Almaqhawi A, Ahmad E, Arsenyadis F, Webb DR, Herring LY, Khunti K, Davies MJ, Yates T. The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews. 2023 Apr;24(4):e13553. doi: 10.1111/obr.13553
Yates T, Sargeant JA, King JA, Henson J, Edwardson CL, Redman E, Gulsin GS, Brady EM, Ahmad E, Stensel DJ, Webb DR. Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Diabetes care. 2022 Nov 1;45(11):2749-52. doi: 10.2337/dc22-0888
Sargeant JA, King JA, Yates T, Redman EL, Bodicoat DH, Chatterjee S, Edwardson CL, Gray LJ, Poulin B, Waheed G, Waller HL. The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2022;24(8):1509-21. doi: 10.1111/dom.14721
Webb DR, Htike ZZ, Swarbrick DJ, Brady EM, Gray LJ, Biglands J, Gulsin GS, Henson J, Khunti K, McCann GP, Waller HL. A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism. 2020 Jul;22(7):1187-96. doi: 10.1111/dom.14023
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinology and Metabolism 2019. doi: 10.3803/EnM.2019.34.3.247
Gulsin GS, Henson J, Brady EM, Sargeant JA, Wilmot EG, Athithan L, Htike ZZ, Marsh A, Biglands JD, Kellman P, Khunti K, Webb D, Davies MJ, Yates T, McCann GP. Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes. Diabetes Care 2020. doi: 10.2337/dc20-0706
Gulsin GS, Swarbrick DJ, Athithan L, Brady EM, Henson J, Baldry E, Argyridou S, Jaicim NB, Squire G, Walters Y, Marsh A, McAdam J, Parke KS, Biglands JD, Yates T, Khunti K, Davies MJ, McCann GP. Effects of Low-Energy Diet or Exercise on Cardiovascular Function in Working-Age Adults With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded End Point Trial. Diabetes Care 2020. doi: 10.2337/dc20-0129
Sargeant JA, Gray LJ, Bodicoat DH, Willis SA, Stensel DJ, Nimmo MA, Aithal GP, King JA. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis. Obesity Reviews 2018. doi: 10.1111/obr.12719